ARCHIVES

Letter to the Editor

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

NCI, FDA Near Agreement On INDs; Young, Hoogstraten Clash On Rubidazone

January 14, 1977

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

July 27, 2012

Steckel Object To Remarks By Korn Comparing Southern California Centers Unfavorably To NCCP Consortium

November 2, 1984

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

March 30, 2012

NCAB Subcommittee Likes Organ Site Program, Except Smoking-Health

April 30, 1976

Clinical Trials Approved In August 2002 By NCI

September 27, 2002